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ABSTRACT
Current two-dimensional (2D) ultrasonic marker measurements are inherent with intra- and inter-observer 
variability limitations. The objective of this paper is to investigate the performance of conventional 2D 
ultrasonic marker measurements and proposed programmable interactive three-dimensional (3D) marker 
evaluation. This is essentially important to analyze that the measurement on 3D volumetric measurement 
possesses higher impact and reproducibility vis-à-vis 2D measurement. Twenty three cases of prenatal 
ultrasound examination were obtained from collaborating hospital after Ethical Committee`s approval. 
The measured 2D ultrasonic marker is Nuchal Translucency or commonly abbreviated as NT. Descriptive 
analysis of both 2D and 3D ultrasound measurement were calculated. Three trial measurements were taken 
for each method. Both data were tested with One-Sample Kolmogorov-Smirnov Test and results indicate 
that markers measurements were distributed normally with significant parametric values at 0.621 and 0.596 
respectively. Computed mean and standard deviation for both measurement methods are 1.4495 ± 0.46490 
(2D) and 1.3561 ± 0.50994 (3D). ANOVA test shows that computerized 3D measurements were found to be 
insignificantly different from the mean of conventional 2D at the significance level of 0.05. With Pearson’s 
correlation coefficient value or R = 0.861, the result proves strong positive linear correlation between 
2D and 3D ultrasonic measurements. Reproducibility and accuracy of 3D ultrasound in NT measurement 
was significantly increased compared with 2D B-mode ultrasound prenatal assessment. 3D reconstructed 
imaging has higher clinical values compare to 2D ultrasound images with less diagnostics information.
Key words: three dimensional (3D), ultrasound, nuchal translucency (NT), fold thickness, Trisomy, 
Down Syndrome.
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INTRODUCTION
Medical literature has proven that a fetus with 
congenital disease such as Down syndrome, 
heart disease and bone disease will have thicker 
transparent layer of subcutaneous fetal neck or 
called Nuchal Translucency. The term Nuchal 
Translucency was termed by Nicolaides KH, 
pioneer in prenatal Trisomy 21 early assessment at 
Fetal Medicine Foundation (FMF), UK (Nicolaides 
et al. 1992). The formation of this transparent layer 
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of skin was due to blockage of blood or lymphatic 
circulation, resulting accumulation of liquid behind 
fetus’s neck (Souka et al. 2001, Hyett et al. 1995, 
Kagan et al. 2009, Snijders et al. 1998). Single 
marker evaluation of NT can help doctors to 
evaluate the chances of fetal with Down syndrome 
up to 70 % (Abuhamad 2006, Zosmer et al. 1999, 
Todd Rosen and D´Alton 2005). Some previous 
publication used to assess the risk of Trisomy 21, 
scientific name of Down syndrome during early 
pregnancy using NT measurement. Combining with 
pregnancy-induced plasma protein A (Pregnancy 
Associated Plasma Protein-A) and free-Beta 
human chorionic gonadotropin (free beta-human 
Chorionic Gonadotropin), it is possible to drive the 
rate up to 90% (one-stop reference trimester Down 
syndrome screening).
Trisomy 21 disorders or Down syndrome 
is the most common disease of chromosomal 
abnormalities, where the patients’ cell have extra 
copy of 21st chromosomes compared to normal 
paired chromosomes, leading to abnormal structure 
and function of many organs which including mental 
retardation, congenital heart disease, and intestinal 
plugs. The birthrate of Down’s syndrome is 
approximately one in every 800 to 1,000 live births. 
Affected babies are likely to suffer from severe 
mental disabilities and physical disabilities, affecting 
in particular the heart, gastrointestinal tract, eyes and 
ears. Down's syndrome generally lives to adulthood, 
but they need to receive long-term caregivers.
The primary factor of Trisomy 21 is still 
unknown, but scientists have proven that the risk 
of Trisomy is highly associated with mother’s 
age, whereby chances of fetus developing Down 
syndrome are higher for aged mothers. There are a 
few methods to confirm the fetus Trisomy screening: 
Amniocentesis, Chorionic villus sampling (CVS) 
and Percutaneous Umbilical Blood Sampling 
(PUBS) to extract amniotic fluid or fetus blood 
cell for genetic testing. Both methods are invasive 
examination with at least 1 percent risk of fetal loss; 
therefore, if the fetuses have low chances of being 
Trisomy 21 babies, these invasive examinations are 
not recommended for pregnant women.  Current 
practices in clinical field are using ultrasonic 
prenatal examination, combining with maternal 
serum markers to assess the preliminary Trisomy 21 
risk (Wee et al. 2010a, b, Nicholas et al. 1988).
Ultrasound medical imaging is widely 
used in clinical application due to its intuitive, 
convenience, safety, non-invasive, and low cost 
(Larose et al. 2003, Orlandi et al. 2003, Malone 
et al. 2004, Wee and Supriyanto 2010, Wee et al. 
2010c, d, Otano et al. 2002). Recent studies show 
that fetal abnormalities can be detected through 
assessment of specific ultrasound markers such as 
nuchal translucency (NT), nasal bone, long bone 
biometry and Doppler assessment of ductus venous 
(Zoppi et al. 2003, Bekker et al. 2004, Recep et al. 
2008, Cicero et al. 2003a, b, 2001). Among these 
markers, sonographic examination of the nuchal 
translucency (NT) between 11 and 14 weeks’ 
gestation has been suggested as the most powerful 
screening method for trisomies, triploidy, and 
Turner syndrome (Nicolaides et al. 1999, Szabo 
and Gallen 1990). Some publications indicate that 
an increased NT thickness greater than 2.5 mm in 
between 10 and 13 weeks plus six days has also 
been associated with an increased risk of congenital 
heart and genetic syndrome (Pandya et al. 1994).
Meanwhile, some researchers suggested that NT 
of larger than 3 mm is associated with an increased 
risk for aneuploidy and other fetal anomalies (Pajkrt 
et al. 1999, Schwarzler et al. 1999). Trans-abdominal 
sonographic examinations are widely used to show 
the mid-sagittal image of the fetal neck to measure 
the nuchal fold. Trans-vaginal ultrasound of NT 
appears to be a more accurate method (Braithwaite 
and Economides 1995) due to increased resolution. 
Conversely, when using a trans-abdominal probe, the 
examiner possesses a wider range of maneuverability 
to obtain the correct mid-sagittal view of the fetus 
(Cullen et al. 1989).
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According to FMF, this transparent layer 
of subcutaneous fetal neck can be accurately 
measured between 11 to 14 weeks with criteria; (a) 
crown hip length to be within the 45-85 mm, (b) 
fetus must be in supine position, (c) do not bend the 
neck of fetal, (d) enlarge fetal image, and (e) note 
the amniotic membrane or umbilical cord near the 
impact of measurement. (e) maximum thickness in 
true sagittal plane is considered as NT thickness. 
Generally, the measurement of fetal NT layer takes 
at least 15 minutes (Taipale et al. 1997), if the fetus 
is not in the right position, the overall prenatal 
screening will consume longer time.
Nevertheless, special training and experiences 
for NT marker assessment are required in order to be 
qualified in manual NT ultrasound screening.  Such 
training is provided by FMF and their competencies 
need to recertify after each year. Besides, conventional 
B-mode ultrasound NT measurements have 
limitations due to inter- and intra-observer variability 
(Pandya et al. 1995, Kanellopoulos et al. 2003). The 
measurement consistency cannot be guaranteed and is 
always subject to human errors, technical difficulties, 
patient loads, and longer time consumptions.  The most 
obstacles for current 2D assessment are choosing the 
correct 2D sagittal plane which consists of maximum 
NT thickness (Supriyanto et al. 2010).  Sonographer 
will choose three best sagittal planes based on their 
experience, and compute the average of three NT 
measurements as the final marker thickness.
Efforts have been made by numerous 
investigators worldwide to find an approach for 
boundary detection in ultrasonic NT images which 
is less reliant on human operators. As it reduces 
the amount of human intervention, it will also 
reduce inter-observer variability and be expected to 
reduce intra-observer variability and consequently 
reduce the drifting problem in measurements 
over time in longitudinal studies. Therefore, 
we have extended the current NT measurement 
from 2D ultrasound to 3D volumetric ultrasound 
in order to overcome all the limitations above. 
In present research, we have implemented the 
generic computing for 3D volumetric ultrasound 
reconstruction using open-source visualization 
toolkits (VTK). We have investigated the 3D NT 
thickness based on developed cell-pick command 
derived from 3D Euclidean distance. In order to 
analyze the significance of proposed method in 
terms of consistency, accuracy and correlations, 
conventional 2D and proposed computerized 3D 
program results were evaluated and compared.
The paper is organized as follows. In Section 
II, algorithm designs of VTK for extended 3D 
visualization reconstructions are described. 
Presentations of 3D NT thickness were simulated 
on 3D volumetric ultrasound rendering. Section 
IV shows the result comparison and analysis for 
conventional B-mode ultrasound and proposed 3D 
measurement method. Finally, we summarize with 
discussions and conclusion.
MATERIALS AND METHODS
The developed 3D reconstructions and computerized 
rendering program are based on open-sources object-
oriented visualization toolkit VTK. The integrated 
IDE environment is Microsoft Visual Studio 8.0 
in Windows 7 using C++ language programming, 
where the initial project file can be built using CMake 
2.80 while configuring external libraries including 
OpenCV 2.2, VTK 5.4, FLTK 1.1, OpenIGTLink 
1.0 and ITK 3.2. VTK is a free computer graphics 
library specialized for 3D image processing 
and visualization. It has excellent structure and 
operating mechanism, hence it is widely used in 
the international visualization research field. We 
have described the detail algorithm design for 3D 
reconstruction in previous publication work (Wee 
et al. 2011, 2012). In this paper, we will focus on 
Observer command design, and real patient data 
collection for 3D NT simulation.
VTK rendering scene can be divided into 
two models, operator 3D widget model and 
renderer data model. In order to update the 
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control information of operator 3D widget model 
on renderer data model, Callback command is 
required to activate the response accordingly. The 
AddObserver acts as an external module to observe 
and reflects the real time data model status. In 
current studies, computing 3D measurement of NT 
is accomplished using vtkPicker widget. Observer 
will convert the vtkPicker data into geometrical 
and physical parameters in the rendering scene. 
Once vtkPicker updates its parameters, Observer 
will update the data simultaneously through the 
interface connection established.
Fig. 1 shows the algorithm connection for 
3D NT thickness measurements through user 
mouse’s interaction. The proposed system will 
send mouse and keyboard input messages to 
vtkPicker through command updating. For the three 
dimensional Euclidean distance computation, two 
world coordinates are required. The point picker 
in computer screen contains only two dimensional 
coordinates, which has no direct relation with the 
three dimensional objects, and therefore, conversion 
into world coordinates is necessary. The distinct 
difference between two dimensional coordinates 
and world coordinates is the latter contains 
depth information, which reflects the depth of 
Z-coordinate spaces. In current studies, the selected 
two dimensional coordinates will be introduced as a 
straight line extended into Z spacing, which might 
penetrate the three dimensional rendering objects 
followed by acquiring the coordinate intersection 
with the surface of rendering objects. Straight line 
may intersect with more than one plane; therefore, 
several interactions are possible. The algorithms then 
compare the distance of all the intersecting points 
with the initial point coordinates. The coordinates 
with the shortest distance calculated will be selected 
as the three dimensional world coordinates.
Fig. 2 shows part of the data collection for the 
same patient with anonymous privacy data, which 
demonstrated the inconsistency of 2D manual 
thickness measurement. For instance, these three 
trials measurement have maximum deviation up to 
0.21mm in this example.
Fig. 1 - Algorithm connection between vtkPicker and renderer data channel for 3D Euclidean computation.
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The deviation measurement can be larger, as 
the operator changes the position of sagittal view 
during prenatal screening. Selecting the correct 
sagittal plane is crucial, which is very subjective 
and relies on personal experiences and technical 
skills. Fig. 3 shows the simulation of 3D NT 
measurement using VTK reconstructions.
RESULTS AND ANALYSIS
Total numbers of 23 patient data were collected from 
collaborated hospital after Ethical Committee approval 
from November 2010 until February 2011. The 
measured ultrasonic marker is nuchal translucency, or 
simply NT, using conventional 2D B-mode prenatal 
ultrasound scan protocol. The type of transducer 
implemented in current examination is abdominal 
probe, with beam form 3.5MHz frequency. The target 
group of examined patients was pregnant women in 
first trimester, or early second trimester singleton 
pregnancies. Populations included are only Malaysian, 
and three trials 2D ultrasonic NT measurements for 
each patient were taken. The three trials 3D measure-
ments were carried out using our developed 3D 
reconstruction and measurement program.
For numerical statistics analyses, Table I 
and Table II show the difference of their standard 
deviations. All the statistics analyses were 
calculated using SPSS 19 software (IBM SPSS 
Statistics). The range of the deviation from mean in 
Table I (2D) are much larger compared to Table II 
(3D), varies from minimum values 0.04041 (P22) 
to maximum values 0.28449 (P21) in 2D, and 
minimum values 1.36E-16 (P11) to maximum values 
0.110151 (P10) in 3D respectively.
Fig. 2 - Three trials manual B-mode Ultrasound sonogram measurement results large variability, 
(a) NT thickness = 1.64mm, (b) NT thickness = 1.43mm, (c) = NT thickness = 1.50mm.
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Fig. 3 - Three dimensional nuchal translucency simulation (a) 3D volumetric rendering (b) Slicing 
view to show for NT segmentation (c) Thickness measurement using 3D Euclidean approach.
TABLE I
Summary of 2D data collection for B-mode ultrasonic NT marker measurement.
Patient Trial 1 Trial 2 Trial 3 Trial Mean, χ Standard Deviation, S Variance, σ2
Maximum 
Range
P1 1.64 1.43 1.50 1.52333 0.10693 0.01143 0.21
P2 1.46 1.66 - 1.56 0.14142 0.02 0.2
P3 1.45 1.60 1.82 1.62333 0.1861 0.03463 0.37
P4 1.16 1.10 1.06 1.10667 0.05033 0.00253 0.1
P5 1.50 1.70 - 1.6 0.14142 0.02 0.2
P6 1.09 0.86 0.80 0.91667 0.15308 0.02343 0.29
P7 1.90 1.83 1.96 1.89667 0.06506 0.00423 0.13
P8 1.33 1.40 - 1.365 0.0495 0.00245 0.07
P9 1.60 1.43 - 1.515 0.12021 0.01445 0.17
P10 1.73 1.88 1.51 1.70667 0.1861 0.03463 0.37
P11 1.04 1.25 1.32 1.20333 0.14572 0.02123 0.28
P12 1.55 1.76 1.69 1.66667 0.10693 0.01143 0.21
P13 0.85 1.09 1.26 1.06667 0.20599 0.04243 0.41
P14 0.99 1.09 - 1.04 0.07071 0.005 0.1
P15 1.20 0.94 1.02 1.05333 0.13317 0.01773 0.26
P16 1.10 1.04 1.26 1.13333 0.11372 0.01293 0.22
P17 1.09 1.27 - 1.18 0.12728 0.0162 0.18
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The data distributions for both cases were 
illustrated in Fig. 4 and Fig. 5, showing the 
histogram of Gaussian bell shape data distribution 
for conventional 2D and our computerized 3D 
ultrasonic marker measurement, which imply 
that the data follow the General Linear Model 
(GLM) foundation.
Computed mean and standard deviation for both 
measurement methods are 1.4495 ± 0.46490 (2D) 
and 1.3561 ± 0.50994 (3D). Note that one extreme 
data dispersion from the bell shape is the only case 
from existing data collection with high risk Trisomy 
21 syndrome (P20), where the measurement is larger 
than 2.5mm (based on guideline from FMF, Fetal 
TABLE II
Summary of proposed 3D NT computation analysis.
TABLE I (continuation)
Patient Trial 1 Trial 2 Trial 3 Trial Mean, χ Standard Deviation, S Variance, σ2
Maximum 
Range
P1 1.52 1.64 1.64 1.6 0.069282 0.0048 0.12
P2 1.6 1.4 1.44 1.48 0.10583 0.0112 0.16
P3 1.83 1.88 1.86 1.856667 0.025166 0.000633333 0.03
P4 1.11 1.09 1.15 1.116667 0.030551 0.000933333 -0.04
P5 1.98 1.9 1.94 1.94 0.04 0.0016 0.04
P6 0.74 0.69 0.69 0.706667 0.028868 0.000833333 0.05
P7 1.64 1.74 1.68 1.686667 0.050332 0.002533333 0.06
P8 1.03 0.99 1.04 1.02 0.026458 0.0007 0.04
P9 1.36 1.39 1.38 1.376667 0.015275 0.000233333 0.02
P10 1.02 1.22 1.2 1.146667 0.110151 0.012133333 0.18
P11 0.95 0.95 0.95 0.95 1.36E-16 1.84889E-32 0
P12 1.61 1.49 1.59 1.563333 0.064291 0.004133333 0.12
P13 1.09 1.04 1.03 1.053333 0.032146 0.001033333 0.06
P14 1.15 1.29 1.31 1.25 0.087178 0.0076 0.16
P15 1.44 1.39 1.45 1.426667 0.032146 0.001033333 0.06
P16 1.3 1.25 1.31 1.286667 0.032146 0.001033333 0.06
P17 1.15 1.09 1.17 1.136667 0.041633 0.001733333 0.08
P18 0.93 0.88 0.91 0.906667 0.025166 0.000633333 0.05
P19 1.8 1.69 1.72 1.736667 0.056862 0.003233333 0.11
P20 3.36 3.32 3.17 3.283333 0.100167 0.010033333 0.19
P21 1.29 1.19 1.26 1.246667 0.051316 0.002633333 0.1
P22 1.33 1.37 1.38 1.36 0.026458 0.0007 0.05
P23 1.24 1.27 1.28 1.263333 0.020817 0.000433333 0.03
Patient Trial 1 Trial 2 Trial 3 Trial Mean, χ Standard Deviation, S Variance, σ2
Maximum 
Range
P18 0.92 1.03 - 0.975 0.07778 0.00605 0.11
P19 1.78 1.64 1.93 1.78333 0.14503 0.02103 0.29
P20 3.05 3.13 3.22 3.13333 0.08505 0.00723 0.17
P21 1.75 1.23 1.29 1.42333 0.28449 0.08093 0.52
P22 1.35 1.35 1.42 1.37333 0.04041 0.00163 0.07
P23 1.53 1.28 1.10 1.30333 0.21595 0.04663 0.43
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Medicine Foundation, UK). To confirm the normal 
distribution of the analyses data with parametric 
symmetry, Kolmogorov-Smirnov Test can be used 
from SPSS, as shown in Table III. 2D and 3D nuchal 
translucency ultrasonic markers measurements were 
distributed normally with significant parametric 
values at 0.621 and 0.596 respectively.
For analysis comparison, we have computed 
the correlation matrix to reveal the consistency of 
measurement for all three trials in both cases. Fig. 6 
and Fig. 7 illustrate the scattered plot points which 
are more widely dispersed in 2D measurement 
compared to the results of 3D program. Table IV 
shows the summary of descriptive statistics analysis 
of overall measurement.
Referring to Table IV, both 2D and 3D 
measurements show a positive value of skewness, with 
values 2.168 and 2.538 respectively. This indicates that 
both distributions have an asymmetric tail extending 
out to the right, which is referred to as “positively 
skewed” or “skewed to the right”. Great skewness may 
also imply the existence of outliers in data.
Besides, both 2D and 3D measurements show 
positive kurtosis, which indicates a “peaked” 
distribution or known as leptokurtic distribution. 
3D measurement has a higher kurtosis compared 
to 2D. This implies that the distribution tends to 
have a distinct peak near the mean, decline rather 
rapidly with heavy tails.
Fig. 4 - Histogram of two dimensional ultrasound nuchal translucency 
thicknesses distributions.
Fig. 5 - Histogram of three dimensional ultrasound nuchal translucency 
thickness distributions.
Fig. 6 - Matric scatter plot for three trials 2D 
ultrasonic NT measurement (Sample Size N = 23).
Fig. 7 - Matric scatter plot for three trials proposed 
3D ultrasonic NT measurement (Sample Size N = 23).
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Based on figures above, we observe that 
consistencies of 2D ultrasonic measurement using 
manual sonogram are obviously prone to inter- and 
intra-observer variability such as subjective human 
errors, experiences, long measurement time, patient 
loads and others.
ANOVA is the variance analysis used to test 
if all means were significantly equal. In our cases, 
we applied the average values of all three trials 2D 
measurements as the reference point for each patient 
assessment. Based on Table V, the measurements 
were tested in pairs and it showed that two out of 
three trials 2D measurement (NT_2D_1 = 0.018 and 
NT_2D_3 = 0.039) were significantly different from 
the references point with P > 0.05. Meanwhile the 
latter three trials 3D measurements were found to 
Fig. 8 - Boxplot of nuchal translucency thickness (mm) in relation to 
2D and 3D measurements (Sample size N=23).
be insignificantly different at the same P level. The 
results prove the reproducibility of 3D measurement.
Fig. 8 illustrates the relationship of data 
distribution for the sample’s range, median, 
normality, and skewness. There were 50% of the 
2D NT measurements greater than 1.37mm, and 
1.25mm for computerized 3D nuchal translucency 
measurement. Twenty five percent were over 1.67mm 
(2D) and 1.56mm (3D), whereas 25% were lower 
than 1.11mm (2D) and 1.05mm (3D). The NT_3D 
measurement indicates that there are high number 
of cases contain within a small segment of the NT 
measurements compared to NT_2D measurement.
Fig. 9 (a) shows a strong positive linear 
relationship between 3D and 2D nuchal translucency 
measurements within Pearson’s correlation 
coefficient values, R = 0.861. In other words, as 
2D nuchal translucency measurement increases, 3D 
nuchal translucency measurement increases as well. 
The computed linear regression line equation is 3D_
NT = (0.945)2D_NT – 0.013. Fig. 9 (b) and (c) show 
the Pearson’s correlation between gestational week 
(GA) and crown rump length (CRL) with 3D nuchal 
translucency measurements, at values R = 0.005 and 
0.017 respectively. The significance F (GA, 0.983; 
CRL, 0.937) is much greater than significant level 
P = 0.05. Results show that 3D nuchal translucency 
variables have no relationship with GA and CRL. 
The equations of linear regression line for GA and 
CRL are NT_3D = (0.001) GA + 1.345 and NT_3D 
= (0.003) CRL + 1.320. The correlation of GA and 
CRL is shown in Fig. 9 (d). As expected, findings 
show a positive relationship between two variables, 
with value R= 0.32. Equation of linear regression 
line for GA and CRL is GA= (0.284) CRL + 9.566.
There is probability of 95% that the slope of 
linear equation falls within the range; 0.692 to 1.198 
mm for NT_3D versus NT_2D; -0.103 to 0.672 mm 
for GA versus CRL; -0.083 to 0.085 mm for NT_3D 
versus GA; and -0.072 to 0.078 mm for NT_3D versus 
CRL. Other than the case of NT_3D versus NT_2D, 
the P-value of the regression slope for the latter three 
cases are higher than 0.05. Thus, we can conclude that 
there is 95% chance that the 95% confidence interval 
for the slopes contains the true value of the slope.
CONCLUSION
Data distribution for 2D and 3D nuchal translucency 
measurements were found to be normally distributed 
with Kolmogorov-Smirnov Test. Consistency of data 
were analyzed using matrix scatter plot. As expected, 
3D measurement had higher consistency compared 
to 2D. Mean value of three trials 2D measurements 
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were used as reference standard. Comparison of 2D 
and 3D measurements with reference standard were 
performed using one way ANOVA for accuracy 
investigation. The relationship among 2D and 3D 
measurements, GA and CRL were modeled using 
Pearson product-moment correlation coefficient. 
Results revealed that 2D measurement is highly 
correlated with 3D measurement (P = 0.05). There 
was no significant relationship established between 3D 
nuchal translucency measurements and GA or CRL.
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RESUMO
As atuais medições bidimensionais (2D) com marcadores 
ultrassônicos com inerentes intra- e interobservadores 
têm limitações de variabilidade. O objetivo deste trabalho 
é investigar o desempenho de medições convencionais 
2D com marcador ultrassom e uma proposta  interativa 
tridimensional programável de avaliação com marcador 
(3D). Isto é essencialmente importante para analisar que 
Fig. 9 - Correlation analysis among four different variables, (a) correlation between 3D and 2D nuchal translucency measurements, 
(b) correlation between 3D nuchal translucency and gestation week (GA), (c) correlation between 3D nuchal translucency and crown rump 
length (CRL), (d) correlation between gestation week and crown rump length.
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a medição em 3D volumétrica possui maior impacto e 
medição de reprodutibilidade vis-à-vis a 2D. Vinte e três 
casos de ultrassonografia pré-natal foram obtidos  do 
hospital que colaborou com a pesquisa após a aprovação pela 
Comissão de Ética. A medida do marcador 2D ultrassônica 
é Translucência Nucal ou comumente abreviado como NT. 
A análise descritiva de medição de ultrassom 2D e 3D foram 
calculados. Três medidas foram obtidas em ensaios para 
cada método. Ambos os dados foram testados com uma 
amostra de teste de Kolmogorov-Smirnov e os resultados 
indicam que as medições de marcadores foram distribuídos 
normalmente com significativos valores paramétricos 
de 0,621 e 0,596, respectivamente. A  média e o desvio 
padrão para ambos os métodos de medição são 1,4495 ± 
0,46490 (2D) e 1,3561 ± 0,50994 (3D).O teste ANOVA 
mostrou que  medições computadorizadas 3D foram 
insignificantemente diferentes da média  2D convencional 
com nível de significância de 0,05. Com coeficiente de 
correlação de Pearson com valor R = 0,861, o resultado 
comprova forte correlação linear positiva entre medidas 
ultrassônicas 2D e 3D . Reprodutibilidade e exatidão do 
ultrassom 3D na medida da TN foram significativamente 
aumentadas em comparação com a  avaliação ultrassom 
2D na modalidade B-pré-natal. Imagem reconstruída 
em 3D tem maiores valores clínicos em comparção 
com as imagens de ultrassom 2D que possuem menos 
informações para diagnóstico.
Palavras-chave: três dimensões (3D), ultrassonografia, 
medida da translucência nucal (TN), espessura da prega, 
Trissomia, síndrome de Down.
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